Breast Cancer Clinical Trial
Official title:
The NCl Community Cancer Center Program Patients Reported Symptom Surveillance and Disparities Study
Background:
- Cancer and cancer treatments can cause symptoms and side effects. Pain, fatigue, and
emotional distress are three common symptoms. Accurate reporting of these symptoms can
improve treatment methods and outcomes. Even though symptom reporting is important to
treatment, there is no method to collect and compare patient data from multiple cancer care
centers. Researchers want to develop a method for collecting cancer patient symptom
information from multiple centers. This method may help improve cancer treatment at hospitals
and other care centers.
Objectives:
- To collect patient-reported symptom information from multiple cancer care centers.
Eligibility:
- Individuals at least 21 years of age who were treated for breast or colon cancer in the
past year.
- Participants will come from one of the participating cancer care centers.
Design:
- Participants will answer a short questionnaire about their symptoms during cancer
treatment. Questions will ask about symptom severity and experiences. Other questions
will ask how well the doctors and nurses managed the symptoms.
- Participant responses will be compared with other medical and personal information. This
information may include cancer type, age at diagnosis, and type of treatment.
- Treatment will not be provided as part of this study.
Background:
- Cancer and its treatment lead to symptoms and side effects. Pain, fatigue, and emotional
distress are three of the most common and distressing symptoms. Patient report is the
gold standard for assessing these symptoms and is critical to patient-centered care.
- Symptoms are often under-reported or under-treated leading to impairments in quality of
life, functioning, and treatment adherence. Factors contributing to
under-reporting/treatment occur within patients (e.g., fear of addiction to pain meds),
providers (e.g., lack of training), and the healthcare system (e.g., under-insurance).
- A limited number of studies suggest that the burden symptoms falls unevenly on certain
racial/ethnic, socioeconomic status (SES), and insurance status groups.
- Despite the importance of symptoms in cancer care, there is no method for systematically
collecting patient reported data at institutional or national levels. Such a system
could identify at risk groups, inform intervention, and ultimately improve quality of
care.
- This study uses existing resources to design a cost-effective symptom surveillance
system. The NCI Community Cancer Center Program (NCCCP) provides the infrastructure for
efficiently conducting a multi-site pilot in a real-world setting with a diverse sample
of patients. The Commission on Cancer s Rapid Quality Reporting System (RQRS) will
automate sampling to minimize burden on the cancer center s staff, facilitate data
collection during or soon after treatment, and protect patients personal identifiers.
The survey instrument is based upon previously validated measures.
Objectives:
- To pilot a method for collecting patient reports of symptom-related experiences that
could be used for surveillance at institutional and, in the future, population levels.
- To investigate disparities in symptom burden and management between racial/ethnic, SES,
and health insurance status groups.
- To pilot the use of patient-reported symptom data for quality improvement of symptom
management at participating cancer centers.
Eligibility:
- Diagnosed with Stage I-III breast or colon cancer as first primary cancer between
February 2011 and January 2013
- Age of 21 years or older
- Received cancer care from one of 17 participating NCCCP Cancer Centers.
Design:
- This cross-sectional survey will collect reports of symptoms and related experiences
from patients 3-12 months after cancer diagnosis via mailed questionnaire. A
methodological experiment will randomize patients after the second mailing to compare
telephone follow-up to a third mailing. Data on cost and Cancer Center staff time will
be collected to provide scalable estimates of overall cost and examine
cost-effectiveness of telephone follow-up.
- The study will provide prevalence estimates for various symptoms and symptom management
items. More complex, model-based statistics will be used to investigate symptom
disparities (Aim 2). For these models, outcomes will be either continuous (e.g., pain
severity) or ordinal (e.g., symptom management items) and will be analyzed using
Generalized Linear Mixed Models (GLMM) to take into account the two-level structure of
the data (patients nested within Cancer Centers). We expect to enroll 2,550 patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |